Prognosia (Acquired by Lunit)
Category: AI in Healthcare
AI-powered software for predicting a woman's personalized five-year risk of developing breast cancer from mammogram images (now Lunit INSIGHT Image-based Risk) Prognosia (Acquired by Lunit) was founded in 2024. The company is led by N/A - Company Acquired. Based in St. Louis, USA (acquired by Seoul-based Lunit). Team size: N/A - Acquired. Total funding raised: Not publicly disclosed - acquired by Lunit. Latest round: Acquired by Lunit (acquisition amount not disclosed). Key investors include Washington University, BioGenerator Ventures, Lunit (acquirer).
- Founded
- 2024
- Headquarters
- St. Louis, USA (acquired by Seoul-based Lunit)
- Team size
- N/A - Acquired
- Total funding
- Not publicly disclosed - acquired by Lunit
Value proposition
Provides accurate, personalized five-year breast cancer risk prediction from mammogram images without requiring patient questionnaires, enabling preventative conversations and tailored screening strategies
Products and solutions
Lunit INSIGHT Image-based Risk (formerly Prognosia Breast) - AI-driven software that analyzes mammogram images to generate a breast cancer risk score
Unique value
The technology provides a personalized five-year risk assessment for breast cancer based solely on mammogram images and age, moving beyond traditional risk models that rely on multiple variables and patient questionnaires
Target customer
Healthcare providers, radiologists, and hospitals (through Lunit's distribution network)
Industries served
Healthcare, Medical Imaging, Oncology, Radiology
Technology advantage
FDA Breakthrough Device designation received in 2025, backed by research from Washington University School of Medicine, now integrated into Lunit's global distribution network
How they differentiate
Prognosia's AI technology analyzes mammograms to predict a woman's five-year risk of developing breast cancer without requiring patient questionnaires, even when the scan appears normal to the human eye
Main competitors
Clairity Breast, iBRISK, Volpara Health (now also owned by Lunit)
Key partnerships
Washington University School of Medicine in St. Louis (technology origin), Lunit (acquirer and commercialization partner)
Notable customers
Now accessible through Lunit's customer base and partnerships
Major milestones
Development of AI-based breast cancer prediction technology, Received FDA 'Breakthrough Device' designation in 2025, Acquired by Lunit in 2025, FDA 510(k) application submitted December 2025
Growth metrics
Technology now processes through Lunit's platform, which has analyzed over 1 million mammograms in the US
Market positioning
Technology is now positioned as part of Lunit's comprehensive breast cancer AI portfolio, combining with Volpara's clinical risk assessment tools
Geographic focus
Global through Lunit's international presence, originally focused on United States
Patents and IP
Specific patent information not publicly available, but technology is protected through FDA Breakthrough Device status
About N/A - Company Acquired
N/A - Company was co-founded by Graham Colditz (MD, DrPH) and Joy Jiang (PhD) who remain at Washington University School of Medicine